Abdul Azeez

Jehan Saldin

SPEEDA Edge - Top Picks - Healthcare & Pharma

Health + Pharma Hero Image

Healthcare & Pharma top picks: AI and personalization fuel new era of health innovation

<div>
  <ul>
    <li>
      <p>
        AI-driven drug discovery is significantly reducing R&amp;D time and costs, with startups nearing commercialization.
      </p>
    </li>
    <li>
      <p>
        Health and pharma companies are using novel technologies such as gene editing, cell therapeutics, and nanopore sequencing to provide tailored healthcare and treatments. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
  <ul>
    <li>
      <p>
        Generative biology is one of the newest tools in the AI drug discovery toolbox; it focuses on designing entirely new therapeutics from scratch using GenAI
      </p>
    </li>
    <li>
      <p>
        Demand is driven by the promise of higher clinical success rates and the ability to treat &lsquo;undruggable&rsquo; diseases&nbsp;
      </p>
    </li>
    <li>
      <p>
        Players include AI-first drug discovery startups, and Big Pharma and Big Tech incumbents entering the space through partnerships
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <ul>
    <li>
      <p>
        Generative biology is one of the newest tools in the AI drug discovery toolbox, and refers to the design of novel biomolecules with desired structures and properties using existing protein data. It combines generative AI, ML, innovations in biology, and automation to create these new protein therapeutics.
      </p>
    </li>
    <li>
      <p>
        Demand is driven by the potential for generative biology to be used to design therapeutics for &quot;undruggable&quot; diseases. In addition, its use in the drug discovery process can increase the accuracy of the newly designed therapeutics thereby increasing the success of clinical trials.
      </p>
    </li>
    <li>
      <p>
        Players in this space include several AI-first drug discovery companies that have adopted generative biology, as well as Big Pharma and Big Tech incumbents that have entered the space through partnerships with startups.
      </p>
    </li>
    <li>
      <p>
        To generate new protein designs, AI/ML models must be trained on the many naturally occurring protein sequences to recognize complex patterns within them. The more data they are fed, the better their output.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


The LEGO of life: Building new organisms with generative biology

<div>
  <ul>
    <li>
      <p>
        The top 100 early-stage startups that are at the forefront of innovation and most likely to outperform on growth metrics in the next 1-2 years
      </p>
    </li>
    <li>
      <p>
        Full report contains details on methodology, approach, and scoring framework, along with a look back at how startups, featured in 2022, have fared
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


EDGE100: The rising startups at the forefront of innovation

<div>
  <ul>
    <li>
      <p>
        All you need to know about the growth companies of tomorrow
      </p>
    </li>
    <li>
      <p>
        Sustainability startups score big in this year&rsquo;s EDGE100
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


EDGE Insights